Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 29286M105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
0% |
8/14/2026
Event 6/30/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||
| VHCP Co-Investment Holdings III, LLC | 0% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||
| VHCP Management III, LLC | 0% | ||
| VHCP Management EG, LLC | 0% | ||
| Nimish Shah | 0% | ||
| Bong Y. Koh | 0% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
Acorn Bioventures, L.P.
13G
|
5.0% |
7/22/2026
Event 7/20/2026
|
|
| Acorn Bioventures, L.P. | 2.1% | ||
| Acorn Capital Advisors GP, LLC | 2.1% | ||
| Acorn Bioventures 2, L.P. | 2.9% | ||
| Acorn Capital Advisors GP 2, LLC | 2.9% | ||
| Anders Hove | 5.0% | ||
|
Cormorant Asset Management, LP
13G/A
Amendment 1
|
0% |
5/15/2026
Event 3/31/2026
|
|
| Cormorant Asset Management, LP | 0% | ||
| Bihua Chen | 0% | ||
| BML Investment Partners, L.P. 13G/A Amendment 1 | 10.0% |
5/14/2026
Event 5/12/2026
|
|
| BML Investment Partners, L.P. 13G | 7.8% |
5/13/2026
Event 5/8/2026
|
|
|
Kynam Capital Management, LP
13G/A
Amendment 1
|
2.2% |
2/17/2026
Event 12/31/2025
|
|
| Kynam Capital Management, LP | 2.2% | ||
| Kynam Capital Management GP, LLC | 2.2% | ||
| Yue Tang | 2.2% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
7.1% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | ||
| VHCP Co-Investment Holdings III, LLC | 7.1% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7.1% | ||
| VHCP Management III, LLC | 7.1% | ||
| VHCP Management EG, LLC | 7.1% | ||
| Nimish Shah | 7.1% | ||
| Bong Y. Koh | 7.1% | ||
|
Cormorant Asset Management, LP
13G
|
6.0% |
2/17/2026
Event 12/31/2025
|
|
| Cormorant Asset Management, LP | 6.0% | ||
| Bihua Chen | 6.0% | ||
|
Invus Global Management, LLC
13G
|
6.3% |
1/27/2026
Event 1/21/2026
|
|
| Invus Public Equities, L.P. | 5.5% | ||
| Invus Public Equities Advisors, LLC | 5.5% | ||
| Invus Global Management, LLC | 5.5% | ||
| Siren, L.L.C. | 5.5% | ||
| Avicenna Life Sci Master Fund LP | 0.8% | ||
| Avicenna Life Sci Master GP LLC | 0.8% | ||
| Ulys, L.L.C. | 0.8% | ||
| Raymond Debbane | 6.3% | ||
|
Perceptive Advisors LLC
13G
|
10.0% |
11/18/2025
Event 11/11/2025
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
Deep Track Capital, LP
13G
|
6.7% |
11/18/2025
Event 11/11/2025
|
|
| Deep Track Capital, LP | 6.7% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.7% | ||
| David Kroin | 6.7% | ||
|
Deep Track Capital, LP
13G/A
Amendment 2
|
4.4% |
11/14/2025
Event 9/30/2025
|
|
| Deep Track Capital, LP | 4.4% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 4.4% | ||
| David Kroin | 4.4% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y Koh | 9.9% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
8.9% |
2/14/2025
Event 12/31/2024
|
|
| Deep Track Capital, LP | 8.9% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 8.9% | ||
| David Kroin | 8.9% | ||
|
Foresite Capital Fund VI LP
13G/A
Amendment 1
|
0% |
2/14/2025
Event 9/30/2024
|
|
| Foresite Capital Fund VI, L.P. | 0% | ||
| Foresite Capital Management VI, LLC | 0% | ||
| James Tananbaum | 0% | ||
|
Kynam Capital Management, LP
13G
|
9.8% |
2/14/2025
Event 12/31/2024
|
|
| Kynam Capital Management, LP | 9.8% | ||
| Kynam Capital Management GP, LLC | 9.8% | ||
| Yue Tang | 9.8% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
3.0% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 3.0% | ||
| Robert Atchinson | 3.0% | ||
| Phillip Gross | 3.0% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
1.8% |
1/29/2025
Event 1/27/2025
|
|
| Biotechnology Value Fund L P | 1.0% | ||
| BVF I GP LLC | 1.0% | ||
| Biotechnology Value Fund II LP | 0.7% | ||
| BVF II GP LLC | 0.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.1% | ||
| BVF Partners OS Ltd. | 0.1% | ||
| BVF GP Holdings LLC | 1.7% | ||
| BVF Partners L P/IL | 1.8% | ||
| BVF Inc/IL | 1.8% | ||
| Lampert Mark N | 1.8% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
5.9% |
1/29/2025
Event 12/31/2024
|
|
| Biotechnology Value Fund L P | 3.1% | ||
| BVF I GP LLC | 3.1% | ||
| Biotechnology Value Fund II LP | 2.5% | ||
| BVF II GP LLC | 2.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 5.5% | ||
| BVF Partners L P/IL | 5.9% | ||
| BVF Inc/IL | 5.9% | ||
| Lampert Mark N | 5.9% | ||
| Fonds de solidarite des travailleurs et des travailleuses du Quebec 13G/A Amendment 1 | 4.5% |
10/21/2024
Event 9/30/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 5 | 11.5 M | $19.9 M |
| 2026 Q1 | 60 | 55.9 M | $381 M |
| 2025 Q4 | 58 | 58.8 M | $531 M |
| 2025 Q3 | 37 | 40.9 M | $279 M |
| 2025 Q2 | 38 | 40.4 M | $147 M |
| 2025 Q1 | 32 | 40.9 M | $183 M |
| 2024 Q4 | 35 | 41.3 M | $275 M |
| 2024 Q3 | 31 | 34.3 M | $228 M |
| 2024 Q2 | 33 | 33.8 M | $318 M |
| 2024 Q1 | 35 | 31.7 M | $536 M |
| 2023 Q4 | 14 | 14.2 M | $131 M |